Erasmus University Medical Center

Erasmus University Medical Center

Name of leader and affiliation
Dr Jurriaan de Steenwinkel, EMC

The Faculty of Medicine and Health Sciences of Erasmus University Rotterdam and the University Hospital Rotterdam have joined forces to form Erasmus MC. The largest centre of its kind in the Netherlands, Erasmus MC provides advanced medical care to 3 million people living in the south-western part of the Netherlands. Care is organized in three clinical branches: the General Hospital; the Sophia Children’s Hospital; and the Daniel den Hoed Oncology Centre. Erasmus MC has achieved excellence in many areas, including cardiovascular diseases, oncology, paediatrics, cell biology & genetics clinical genetics, human reproduction, endocrinology, microbiology, virology immunology hepatology and (micro-) surgery. Erasmus MC is among the top research institutes in the Netherlands and participates in several nationally and internationally recognized research schools. Research activities range from fundamental biomedical research, patient-related research and epidemiology to public health, health care policy and management. Erasmus MC offers basic medical education, followed by specialization tracks to become a general practitioner or a medical specialist. In addition, Erasmus MC offers Master of Science programs, postgraduate courses and researcher training courses. The Erasmus MC employs over 12.000 people.

The National Institute for Public Health and the Environment (RIVM) is a recognised leading centre of expertise in the fields of health, nutrition and environmental protection. We work mainly for the Dutch government. We also share our knowledge with governments and supranational bodies around the world. The results of our research, monitoring, modelling and risk assessment are used to underpin policy on public health, food, safety and the environment. We employ over 1500 employees, many of whom work in multidisciplinary fields.



Sorry, no posts found for this author.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.